Loading clinical trials...
Loading clinical trials...
A 12 Weeks,Multi-center,Randomized,Double-blind,Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of LP-003 in Adult Patients With Inadequately Controlled Moderate to Severe Seasonal Allergic Rhinitis Despite the Current Recommended Therapies
Conditions
Interventions
LP-003 dose 1
LP-003 dose 2
+1 more
Locations
17
China
Beijing Shijitan Hospital
Beijing, Beijing Municipality, China
Dongfang Hospital
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Peking University Third Hospital
Beijing, Beijing Municipality, China
Zhengzhou central hospital
Zhengzhou, Henan, China
Changchun University of Chinese Medicine Affiliated Hospital
Changchun, Jilin, China
Start Date
July 6, 2023
Primary Completion Date
October 19, 2023
Completion Date
August 6, 2024
Last Updated
December 15, 2025
NCT04815668
NCT06846385
NCT06837233
NCT03570957
NCT05540717
NCT02320396
Lead Sponsor
Longbio Pharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions